Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Parabilis Medicines, Inc.
Agenus Inc.
National Cancer Institute (NCI)
ViroMissile, Inc.
Dana-Farber Cancer Institute
University of Florida
Essen Biotech
Angiex, Inc.
Tanabe Pharma America, Inc.
Pfizer
Hangzhou DAC Biotechnology Co., Ltd.
Washington University School of Medicine
3B Pharmaceuticals GmbH
Fudan University
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
NextPoint Therapeutics, Inc.
OncoC4, Inc.
Chinese University of Hong Kong
Elevation Oncology
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Cedars-Sinai Medical Center
TransThera Sciences (Nanjing), Inc.
OHSU Knight Cancer Institute
Charite University, Berlin, Germany
Prelude Therapeutics
M.D. Anderson Cancer Center
pharmaand GmbH
Kineta Inc.
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
MacroGenics
Case Comprehensive Cancer Center
Celgene
InSightec
InSightec
Mirror Biologics, Inc.
Tel-Aviv Sourasky Medical Center
OPKO Health, Inc.
CytoMed Therapeutics Pte Ltd
InSightec
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer